Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 321

Similar articles for PubMed (Select 19576893)

1.

Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.

Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N.

FEBS Lett. 2009 Jul 21;583(14):2435-40. doi: 10.1016/j.febslet.2009.06.047. Epub 2009 Jul 2.

2.

NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF.

J Biol Chem. 2007 Jun 22;282(25):18245-53. Epub 2007 May 7.

3.

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.

Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9. doi: 10.1016/j.ejphar.2009.09.025. Epub 2009 Sep 17.

PMID:
19766111
4.

RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.

Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV.

Exp Cell Res. 2007 Jan 1;313(1):168-78. Epub 2006 Oct 6.

PMID:
17084841
5.

MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.

Kim JH, Kim K, Youn BU, Jin HM, Kim N.

Cell Signal. 2010 Sep;22(9):1341-9. doi: 10.1016/j.cellsig.2010.05.001. Epub 2010 May 11.

PMID:
20466061
6.

Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.

Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR.

Gene. 2009 Oct 15;446(2):90-8. doi: 10.1016/j.gene.2009.06.013. Epub 2009 Jun 27.

PMID:
19563866
7.
8.

The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.

Kim HS, Suh KS, Sul D, Kim BJ, Lee SK, Jung WW.

Int J Mol Med. 2012 Feb;29(2):169-77. doi: 10.3892/ijmm.2011.822. Epub 2011 Oct 31.

PMID:
22038020
9.

NFATc1: functions in osteoclasts.

Zhao Q, Wang X, Liu Y, He A, Jia R.

Int J Biochem Cell Biol. 2010 May;42(5):576-9. doi: 10.1016/j.biocel.2009.12.018. Epub 2009 Dec 24. Review.

PMID:
20035895
10.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
11.

Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.

Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y, Nakamura H, Takahashi N, Udagawa N.

J Bone Miner Res. 2009 Aug;24(8):1469-80. doi: 10.1359/jbmr.090302.

PMID:
19292614
12.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
13.

MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation.

Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, Ostrowski MC.

J Biol Chem. 2007 May 25;282(21):15921-9. Epub 2007 Apr 2.

14.

Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.

Kim MH, Shim KS, Kim SH.

Arch Pharm Res. 2010 Mar;33(3):457-62. doi: 10.1007/s12272-010-0316-0. Epub 2010 Mar 30.

PMID:
20361312
15.

Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.

Park CK, Lee Y, Chang EJ, Lee MH, Yoon JH, Ryu JH, Kim HH.

Biochem Pharmacol. 2008 Jun 1;75(11):2175-82. doi: 10.1016/j.bcp.2008.03.007. Epub 2008 Mar 21.

PMID:
18433733
16.

Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.

Tsuji-Naito K.

Bioorg Med Chem. 2008 Oct 15;16(20):9176-83. doi: 10.1016/j.bmc.2008.09.036. Epub 2008 Sep 14.

PMID:
18823786
17.

Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis.

Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N.

J Biol Chem. 2005 Oct 21;280(42):35209-16. Epub 2005 Aug 18.

18.

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T.

Dev Cell. 2002 Dec;3(6):889-901.

PMID:
12479813
19.

Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.

Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, Kim N.

J Immunol. 2012 Jan 1;188(1):163-9. doi: 10.4049/jimmunol.1101254. Epub 2011 Nov 30.

20.

GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.

Lee MS, Kim HS, Yeon JT, Choi SW, Chun CH, Kwak HB, Oh J.

J Immunol. 2009 Sep 1;183(5):3390-9. doi: 10.4049/jimmunol.0804314. Epub 2009 Jul 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk